Ovarian cancer, version 3.2012.


Journal Article

These NCCN Guidelines Insights focus on the major updates for the 2012 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Ovarian Cancer by describing how and why the new recommendations were made. The 6 update topics were selected based on recent important updates in the guidelines and on debate among panel members about recent clinical trials, and include: 1) screening, 2) diagnostic tests for assessing pelvic masses, 3) primary treatment using neoadjuvant chemotherapy, 4) primary adjuvant treatment using bevacizumab in combination with chemotherapy, 5) therapy for recurrent disease, and 6) management of drug/hypersensitivity reactions. These NCCN Guidelines Insights also discuss why some recommendations were not made (eg, panel members did not feel the new data warranted changing the guideline). See "Updates" in the NCCN Guidelines for Ovarian Cancer for a complete list of all the recent revisions.

Full Text

Duke Authors

Cited Authors

  • Morgan, RJ; Alvarez, RD; Armstrong, DK; Burger, RA; Castells, M; Chen, L-M; Copeland, L; Crispens, MA; Gershenson, D; Gray, H; Hakam, A; Havrilesky, LJ; Johnston, C; Lele, S; Martin, L; Matulonis, UA; O'Malley, DM; Penson, RT; Remmenga, SW; Sabbatini, P; Santoso, JT; Schilder, RJ; Schink, J; Teng, N; Werner, TL; Hughes, M; Dwyer, MA; National Comprehensive Cancer Network,

Published Date

  • November 1, 2012

Published In

Volume / Issue

  • 10 / 11

Start / End Page

  • 1339 - 1349

PubMed ID

  • 23138163

Pubmed Central ID

  • 23138163

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2012.0140


  • eng

Conference Location

  • United States